Cat. No. | Product name | CAS No. |
DC66862 |
Itepekimab
Featured
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD). |
2226742-52-3 |
DC66863 |
Tozorakimab
Featured
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease. |
2376858-66-9 |
DC66864 | Torudokimab Featured | |
DC66865 |
Etokimab
Featured
Etokimab (Antibody ANB 020) is a humanized monoclonal antibody that targets IL-33. Etokimab can be used for the research of atopic dermatitis. |
2022981-44-6 |
DC66866 |
Talacotuzumab
Featured
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models. |
1826831-79-1 |
DC66867 | SNG-CD123A Featured | |
DC66868 | MEDI2045 Featured | |
DC66869 |
Depemokimab
Featured
Depemokimab (GSK-3511294) is a long-acting anti-IL-15 monoclonal antibody. Depemokimab can be used for research of asthma. |
2243274-14-6 |
DC66870 | Abgenix anti-IL-5 Featured |